# **Screening Libraries**

## **Product** Data Sheet

# **Quinidine sulfate**

Cat. No.: HY-B1751A

CAS No.: 50-54-4

Molecular Formula:  $C_{20}H_{26}N_{2}O_{6}S$ Molecular Weight: 373.46

Parasite; Potassium Channel; Cytochrome P450; Apoptosis Target:

Pathway: Anti-infection; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease;

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

### **BIOLOGICAL ACTIVITY**

Description Quinidine Monosulfate is an antiarrhythmic agent. Quinidine Monosulfate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine Monosulfate is also a  $K^+$  channel blocker with an IC $_{50}$  of 19.9  $\mu$ M, and can induce apoptosis.

Quinidine Monosulfate can be used for malaria research<sup>[1][2][3][4]</sup>.

IC <sub>50</sub> & Target	Plasmodium	
In Vitro	Quinidine Monosulfate shows cytotoxicity against MES-SA cells, and induces apoptosis <sup>[4]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.  Cell Cytotoxicity Assay <sup>[4]</sup>	
	Cell Line:	MES-SA and MESSA/DX5 cells
	Concentration:	10 μΜ
	Incubation Time:	24 hours
	Result:	Showed cytotoxicity against MES-SA cells in a concentration-dependent manner.
	Apoptosis Analysis <sup>[4]</sup>	
	Cell Line:	MES-SA and MESSA/DX5 cells

Concentration: 10 μΜ

Incubation Time: 24 hours

Result: Increased the apoptotic portion sub-G1 DNA contents induced by paclitaxel, while paclitaxel had no effect on sub-G1 DNA contents undergoing apoptosis.

In Vivo Quinidine Monosulfate shows effects on the PTZ-induced seizure threshold<sup>[5]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male mice of the NMRI strain (age 5-6 weeks and weight 25-30 g)<sup>[5]</sup>

Dosage:	10, 20, and 30 mg/kg	
Administration:	Intraperitoneal injection; 10, 20, and 30 mg/kg; once	
Result:	Increased the threshold dose for the onset to tonic hind limb extension at a dose of 30 mg/kg, compared to the saline-treated control group (p<0.05).	

### **CUSTOMER VALIDATION**

- J Hazard Mater. 2021 Aug 15;416:125764.
- Environ Int. 2019 Jun;127:694-703.
- J Med Chem. 2021 Mar 11;64(5):2725-2738.
- J Med Chem. 2020 Oct 8;63(19):11085-11099.
- Chemosphere. 2021, 131347.

See more customer validations on www.MedChemExpress.com

### **REFERENCES**

- [1]. Kehl SJ, et al. Quinidine-induced inhibition of the fast transient outward K+ current in rat melanotrophs. Br J Pharmacol. 1991 Jul;103(3):1807-13.
- [2]. Roden DM, et al. Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide.
- [3]. Sang-Yun Lee, et al. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol. 2011 Aug;26(4):424-31.
- [4]. Hassan Jamali, et al. Effect of dextromethorphan/quinidine on pentylenetetrazole- induced clonic and tonic seizure thresholds in mice. Neurosci Lett. 2020 Jun 11;729:134988.
- [5]. Moody DE, et al. Quinidine inhibits in vivo metabolism of amphetamine in rats: impact upon correlation between GC/MS and immunoassay findings in rat urine. J Anal Toxicol. 1990 Sep-Oct;14(5):311-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA